人表皮生长因子受体2低表达乳腺癌相关因素及新辅助化疗疗效研究  

Retrospective study on HER-2 low expression associated factors and efficacy on neoadjuvant chemotherapy

作　　者：杨自国 由晗 朱强[1] 王林[1] 尹子毅[1] 王丕琳[1] 王文彦 Yang Ziguo;You Han;Zhu Qiang(Department of Breast Surgery,Beijing Tiantan Hospital Affiliated to Capital Medical University,Beijing 100050,China)

机构地区：[1]首都医科大学附属北京天坛医院普通外科,北京100050

出　　处：《中华保健医学杂志》2024年第4期491-494,共4页Chinese Journal of Health Care and Medicine

基　　金：北京市科学技术协会青年人才托举工程(NO.BYESS2023226)。

摘　　要：目的 探讨人表皮生长因子受体2(HER-2)低表达乳腺癌与患者临床、病理特征的关系及新辅助化疗疗效。方法 收集2019年8月~2023年4月首都医科大学附属北京天坛医院收治的109例接受新辅助化疗的传统分型HER-2阴性乳腺癌患者的临床资料。观察HER-2低表达乳腺癌穿刺病理分布情况,分析传统分型HER-2阴性乳腺癌患者临床、病理特征与乳腺癌新辅助化疗疗效及HER-2表达的关系。结果 109例传统分型HER-2阴性乳腺癌患者中,HER-2低表达患者占72.5%(79/109),pCR率为12.8%(14/109)。HER-2低表达乳腺癌患者的pCR率为7.6%,低于HER-2无表达乳腺癌患者的26.7%,差异有统计学意义(χ^(2)=7.065,P=0.008)。在传统分型HER-2阴性乳腺癌中,HER-2低表达与雌激素受体(ER)阳性、孕激素受体(PR)阳性、Ki-67 <30%均可能有关(P<0.05)。结论 在传统分型HER-2阴性乳腺癌中,HER-2低表达与患者的ER状态、PR状态、Ki-67水平及新辅助化疗疗效密切相关。Objective To explore the clinicopathological characteristics and response to neoadjuvant chemotherapy of human epidermal growth factor receptor 2(HER-2)low breast cancer.Methods One hundred and nine HER-2 negative breast cancer were enrolled in our cohort for analysis,who were diagnosed in the Department of Breast Surgery,Beijing Tiantan Hospital affiliated to Capital Medical University from August 2019 to April 2023 and received neoadjuvant chemotherapy.Results The pathological complete response(pCR)rate of breast cancer with HER-2 low expression was 7.6%,lower than those with progesterone receptor(PR)positive(26.7%,p=0.008).Among HER-2 negative breast cancer,HER-2 low expression was associated with estrogen receptor(ER)positive(P=0.010),PR positive(P<0.001),and Ki-67<30%(P=0.002).Conclusion Among HER-2 negative breast cancer,HER-2 low expression is closely related to ER,PR status,Ki-67 level and neoadjuvant chemotherapy efficacy.

关 键 词：人表皮生长因子受体2低表达 乳腺癌 新辅助化疗 临床病理特征 

分 类 号：R737.9[医药卫生—肿瘤]